Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | Finanšu pārskati |
Valoda | EN |
Statuss | Atcelts |
Versija | |
Datums | 2011-05-27 16:27:28 |
Versijas komentārs | |
Teksts |
Today, on 27 May, the financial
statement of the JSC “Grindeks” on the first quarter of the year
2011 submitted to “NASDAQ OMX Riga” indicates that the net profit
of the Group of “Grindeks” (hereinafter – the Group) was 1.5
million lats in the reporting period, which is by 0.1 million lats
or 7.1% more in comparison with the first three months of 2010. In
its turn, the Group’s turnover during the first quarter of 2011
amounted to 14 million lats, which is by 0.55 million lats or 4.1%
more than in the first quarter of 2010.
In the first three months of
2011, the gross profit margin of the Group was 57.9%, whereas, the
net profit margin comprised 10.7%. Products of the Group,
manufactured during the reporting period, were exported to 41
countries worldwide for the total amount of 13.2 million
lats.
In the first quarter of 2011 the
sales volume of the final dosage forms of “Grindeks” amounted to
12.45 million lats, which is by 0.17 million lats or 1.4% more than
in the same reporting period of 2010. In the first quarter of 2011,
the amount of “Grindeks” final dosage forms’ export to the main
markets – Russia, other CIS countries and Georgia – remained at the
level of the last year’s first quarter and was 10.4 million lats.
In its turn, the turnover of the final dosage forms in the Baltic
States and other European countries reached 2.05 million lats,
which is by 0.32 million lats or 18.5% more than in the first
quarter of 2010.
In the first three months of 2011
the active pharmaceutical ingredients’ sales volume reached 1.55
million lats, which is by 0.38 million lats or 32.5% more than in
the first quarter of 2010. The main export markets for active
pharmaceutical ingredients of “Grindeks” are Germany, Japan and the
Netherlands. Along with the most demanded active pharmaceutical
ingredients – detomidine, medetomidine, atipamezole etc. – the most
significant increase in demand observed for the active
pharmaceutical ingredient – ursodeoxycholic acid (UDCA), which was
introduced into manufacturing in 2009.
“Grindeks” Member of the Board,
Finance and Administrative Director Vadims Rabša: “In the
pharmaceutical market the competition is fierce,
and there are no reasons to believe
that it could decrease. Our results confirm that we are able to use
our advantages and we are ready
for challenges
to achieve a positive growth in
business indicators. In our
traditional markets – Russia and other CIS countries – the demand
for our ready made medications is stable. But in the new markets of
Eastern Europe and the Balkans, as well as of the Baltic countries
a long-term positive trend and dynamic growth have been already
observed. Business of active
pharmaceutical ingredients takes a larger and larger role, and it
indicates two strategic priorities set before - business
diversification and targeted direction towards vertically
integrated solutions. It enhances the competence and is an
important prerequisite for competitiveness!”
On “Grindeks”
“Grindeks”
is the leading pharmaceutical company in the Baltic States. Its
main fields of action are: research, development, manufacturing and
sale of original products, generics and active pharmaceutical
ingredients. “Grindeks” specializes in the heart and
cardiovascular, CNS and anti-cancer medication therapeutic
groups.
The Group
consists of four subsidiary companies in Latvia, Estonia and
Russia, as well representative offices in ten countries. Products
of the company are exported to 50 countries and its export
comprises more than 95% of the total turnover. The main markets
are: Russia and other CIS countries, the Baltic States,
Germany and the Netherlands. JSC “Grindeks” shares are listed in the Official
List of “NASDAQ
OMXRiga”.
Further
information on the company – www.grindeks.lv
Further
information:
Laila
Klavina
Head of
the Communications Department
JSC
“Grindeks”
Phones: (+371)
67083370, (+371) 29256012
Fax:
(+371) 67083505
E-mail:
laila.klavina@grindeks.lv
|
Pielikumi |
|